GlassScriptPhysician profile
William J Starbird
NPI 1629172069
$8,030.31
in general payments reported to CMS, 2019-2025
20 companies · $339 in 2025
The $339 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $178 · 2020: $165 · 2021: $181 · 2022: $198 · 2023: $6,631 · 2024: $338 · 2025: $339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $4,336 · Travel and Lodging: $1,745 · Food and Beverage: $1,227.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $4,336.00 |
| Travel and Lodging | $1,744.56 |
| Food and Beverage | $1,227.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $6,277.79 | 2021-2023 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Novo Nordisk INC | $521.08 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $221.85 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $149.43 | 2021-2025 | Airsupra, Breztri |
| Abbvie INC. | $126.15 | 2022-2025 | Vraylar |
| Abbott Laboratories | $120.05 | 2021-2024 | Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $85.46 | 2022-2025 | Rexulti, Abilify Maintena |
| Amgen INC. | $84.01 | 2020-2025 | Krystexxa |
| Exact Sciences Corporation | $83.52 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Alkermes, INC. | $80.30 | 2022-2023 | Aristada, Lybalvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.85 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $46.45 | 2024-2025 | Caplyta |
| Pfizer INC. | $44.32 | 2023 | |
| Mayne Pharma Commercial LLC | $27.17 | 2023 | |
| Rgh Enterprises LLC | $27.00 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $23.55 | 2024 | Trelegy Ellipta |
| Supernus Pharmaceuticals, INC. | $16.81 | 2023 | Qelbree |
| Biohaven Pharmaceutical Holding Company LTD. | $12.95 | 2022 | |
| Merck Sharp & Dohme LLC | $11.92 | 2019 | |
| Allergan, INC. | $11.65 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Starbird listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.